| hCT | human calcitonin; human chorionic thyrotropin |
|---|---|
| HEK | human embryo kinase; human embryonic kidney |
| HEL | hen egg white lysozyme; human embryonic lung; human erythroleukemia |
| HES | health examination survey; hematoxylin-eosin stain; human embryonic skin; human embryonic spleen; hy... |
| HG | hand grip; herpes gestationis; Heschl's gyrus; high glucose; human gonadotropin; human growth; hypog... |
| insulin hypoglycaemia test | A test to determine the completeness of vagotomy for peptic ulcer; after the surgical procedure is performed, insulin is administered to cause hypoglycaemia; if vagotomy is complete, the acid output from the stomach following administration of insulin is less than that before insulin administration; if the reverse if true, incomplete vagotomy is likely. Synonym: Hollander test. (05 Mar 2000) |
|---|---|
| insulin infusion systems | Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. (12 Dec 1998) |
| insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| insulin, isophane | <chemical> An intermediate-acting insulin with an approximate time of onset of 2 hours and duration of action of 24 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex with a ratio of free and bound insulin, providing action intermediate between regular insulin and protamine zinc insulin. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin Isophane (12 Dec 1998) |
| insulin, lente | <chemical> Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension conisists of a mixture of crystals and amorphous material in a ratio of approximately 7:3. Pharmacological action: hypoglycaemic agents. Chemical name: Insulin zinc (12 Dec 1998) |
| insulin-like activity | A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like-growth-factor-binding protein 6 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding proteins | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9) (12 Dec 1998) |
| insulin-like growth factor I | <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor. Chemical name: Insulin-like growth factor I (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
믹스타드40hm펜필주100단위/ml - 새창
|
Novo Nordisk |
W08720091 | Human insulin | 전문의약품 | 삭제 | 분업예외의약품 |
|
비오휼린주n.p.h40단위 - 새창
|
동신제약 |
A15105891 | Human insulin | 전문의약품 | 삭제 | 분업예외의약품 |
|
액트라피드HM주100단위/ml - 새창
|
Novo Nordisk |
E08720231 | Human insulin | 전문의약품 | 삭제 | 분업예외의약품 |
|
믹스타드30이노렛100단위/ml(휴먼인슐린) - 새창
|
노보노디스크 |
E08720271 | Human insulin | 전문의약품 | 급여 |
|
노보렛알주100단위/ml - 새창
|
Novo Nordisk |
E08720021 | Human insulin | 전문의약품 | 급여 | 분업예외의약품 |
|
인슈라타드이노렛100단위/ml(휴먼인슐린) - 새창
|
노보노디스크 |
E08720281 | Human insulin | 전문의약품 | 급여 |
|
휴물린Rpen - 새창
|
Lilly |
E00510151 | Human insulin | 전문의약품 | 삭제 | 분업예외의약품 |
|
노보린엔주100단위 - 새창
|
녹십자 |
A35540611 | Human insulin | 전문의약품 | 급여 |
|
베로슈린HM주100단위/ml - 새창
|
노보노디스크 |
E08720241 | Human insulin | 전문의약품 | 급여 | 분업예외의약품 |
|
비오휼린주n.p.h 100단위 - 새창
|
동신제약 |
A15105901 | Human insulin | 전문의약품 | 삭제 | 분업예외의약품 |